Angiodynamics, Inc. ( (ANGO) ) has released its Q1 earnings. Here is a breakdown of the information Angiodynamics, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AngioDynamics, Inc. is a leading medical technology company that focuses on enhancing vascular health, expanding cancer treatment options, and improving patient quality of life through innovative devices and technologies.
In its fiscal year 2026 first-quarter earnings report, AngioDynamics reported significant growth in its Med Tech segment, with a 26.1% increase in net sales, marking the fourth consecutive quarter of over 20% growth. The company also reported an adjusted EBITDA of $2.2 million, a notable improvement from a negative figure in the prior year, and raised its full-year guidance for various financial metrics.
Key financial highlights include a 12.2% increase in net sales to $75.7 million, driven by robust performance in the Med Tech segment. The Auryon peripheral atherectomy platform, thrombus management platform, and NanoKnife system contributed significantly to this growth. The company also achieved a gross margin of 55.3%, reflecting operational efficiencies and increased Med Tech revenue.
AngioDynamics continues to make strides in clinical trials and research, enrolling the first patients in the AMBITION BTK and RECOVER-AV trials and publishing positive results from the NanoKnife PRESERVE study. These efforts underscore the company’s commitment to advancing medical technology and expanding its clinical presence globally.
Looking ahead, AngioDynamics remains optimistic about its financial performance for the rest of fiscal year 2026, with expectations to be cash flow positive and to continue delivering profitable growth through strategic investments and operational excellence.